Engineered immune cells changed spinal fluid in MS
By MS Buddy ·
Summarized from Cell, Nov 2026 · PubMed. AI-generated summary. Not medical advice.
Case series · 5 people with progressive or relapsing-remitting MS (flare-ups followed by recovery)
Research by Felix Fischbach, Manuel Friese and 29 colleagues at University Medical Center Hamburg-Eppendorf, University Hospital Basel and University of Basel and 2 other institutions in Germany, Switzerland and the United States.
Can engineered immune cells change immune activity in spinal fluid in MS?
Key Takeaway
Engineered immune cells changed immune activity in spinal fluid in five people with MS, but effects on symptoms and disease worsening remain untested.

What They Found
Treatment changed the mix of B cells (immune cells that make antibodies) in spinal fluid. Markers linked to antibody activity in spinal fluid stayed lower after treatment. Engineered treatment cells also entered the spinal fluid and showed changes in their activity. B cells returning in the blood showed changes in immune signals and patterns linked to where they travel. These findings suggest the treatment changed immune activity beyond removing B cells from the blood.
Who Should Care and Why
The study involved people with progressive or relapsing-remitting MS (MS with flare-ups followed by periods of recovery). Researchers treated them with their own immune cells, engineered to target B cells (immune cells that make antibodies). The study examined safety-related questions and whether treatment cells reached the brain and spinal cord. It also explored whether immune changes differed between blood and spinal fluid.
Important Considerations
This case series (a report describing treated people without a comparison group) included five people. The abstract does not report whether symptoms, disability, or flare-ups improved. These findings cannot tell you whether the treatment is safe, how long its effects last, or whether it slows MS.
AI-generated summary — for informational purposes only, not medical advice
Read the original abstract
Published in Cell by et al.. Reproduced from the PubMed record.
Multiple sclerosis (MS) is a chronic inflammatory central nervous system (CNS) disease. Although current immunotherapies control relapses, they have limited impact on progression, which might reflect incomplete access to or modulation of compartmentalized CNS inflammation. Chimeric antigen receptor (CAR) T cells can infiltrate tissues, but their ability to access and eliminate immune cells residing in the CNS remains elusive. We report the treatment of five individuals with progressive or relapsing-remitting MS with autologous CD19 CAR T cells to assess safety-relevant aspects, CNS bioavailability, and compartment-specific effects. The intervention induces remodeling of the cerebrospinal fluid (CSF) B cell pool, with a sustained reduction in CSF humoral biomarkers. Notably, CSF-infiltrating CAR T cells selectively upregulate phosphodiesterase 7B, while reconstituted peripheral B cells show altered cytokine and homing profiles. These findings indicate compartment-specific immunomodulation beyond peripheral B cell depletion and support controlled trials to test safety, durability, and efficacy.
Categories
Explore more research
Related MS research

11/20/2026
A review looks at changes in how the body uses tryptophan (a building block of proteins) in MS and o
Read More
11/20/2026
A small study followed brain connections and thinking in early MS over 10 months. Patterns differed
Read More
11/20/2026
A global study including childhood MS found rising rates and disability from rare childhood brain an
Read More
11/20/2026
Removing a protein that restrains immune cells worsened MS-like disease in mice. This laboratory stu
Read More
11/20/2026
Researchers identified disease-driving immune cells in an MS model and related human diseases. Lab f
Read More
11/18/2026
A review finds limited direct evidence that diet, exercise, or gut microbes affect MS through the bo
Read MoreNot all studies carry the same weight: sample size, study design and whether results were replicated all matter. The credibility score above reflects the journal, and the original paper is linked under More Details. Read how MS Buddy selects and scores research, and talk to your MS care team before acting on any study.
